LSP reports first closing of dementia fund
European life sciences investors LSP has closed a new fund to fight dementia at €50m.
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will be managed by Professor Philip Scheltens, a world-renowned dementia scientist and thought leader.
A staggering 50 million patients suffer from dementia worldwide, which is predicted to triple to 150 million before the year 2050. Gobal costs for healthcare systems are currently estimated to amount to over $800bn or 1.1% of global GDP. Yet, investments in R&D to find novel treatments are lagging behind.
The LSP Dementia Funds focus will be on finding novel treatments for neurodegenerative diseases, such as Alzheimer’s disease, that cause dementia, as well as generating a strong financial return for investors.
LSP announced it has yet raised €50m from strategic parties, financial institutions, and family offices. The investors believe the fund will ultimately reach at least €150m.
Biocytogen Co Ltd
Draupnir Bio ApS